Advertisement

Topics

Renovo Limited Company Profile

05:15 EST 21st November 2017 | BioPortfolio

Renovo's core business activity is the development of innovative and efficacious approaches to prevent scarring and enhance tissue repair, from discovery phase to clinically proven commercial product.



Renovo are addressing major market opportunities by developing products initially for scar prevention and subsequently for chronic wound healing. The Company combines considerable basic science and clinical expertise including management personnel with international reputations for research, development, and commercialisation in this area, with a broad and strong intellectual property portfolio consisting of more than 300 patents and patent applications as well as exclusive licencing arrangements to access other key patents required for the development of its lead molecules

Location

Manchester Incubator Building, 48 Grafton Street
Manchester
M13 9XX
United Kingdom

Contact

Phone: 0161 606 7222
Fax: 0161 606 7333
Email: info@renovo.com


News Articles [25 Associated News Articles listed on BioPortfolio]

Renovo Group shares soar as chairman buys 20,000 of them

Shares in Manchester biotechnology business Renovo Group soared to their highest level since March 2008 as chairman Rodger Pannone pitched in to buy 20,000 shares. Mr Pannone paid 48.8p a share. It me...

A new milestone payment to Renovo of $5m from Shire

Other Milestones and Royalty Payments Unchanged Renovo Obtain Right to License and Sell Outside North America and Mexico Renovo Group plc (LSE: RNVO), the biopharmaceutical product company developing ...

Renovo fully recruited on Phase III trials

Juvista EU Phase III Trial Fully Recruited and On Schedule to Report Data in H1 2011 Renovo Group plc, the biopharmaceutical product company developing drugs to reduce scarring, improve wound healing ...

Juvista safety studies following Keloid excision concluded successfully

Renovo Group plc (LSE : RNVO), the biopharmaceutical company developing drugs to reduce scarring, improve wound healing and enhance tissue regeneration, today announces that its Phase I dose ranging c...

Renovo Interim Management Statement

Renovo Group plc (LSE: RNVO), the biopharmaceutical company developing drugs to reduce scarring, improve wound healing and enhance tissue regeneration publishes its Interim Management Statement for th...

Renovo announces major restructuring

Renovo Group plc (LSE: RNVO) announced on 11 February 2011 that its first EU Phase III trial for Juvista® in scar revision surgery (REVISE™) did not meet its primary or secondary endpoints.&...

Appointment of Director

Oxford, UK, 1 November 2017: e-Therapeutics plc (AIM: ETX), a company pioneering the use of Network-Driven Drug Discovery (NDD) to create new and better drugs, announces the appointment of Christine...

Telix Pharmaceuticals Limited Lists on the Australian Securities Exchange

MELBOURNE, Australia, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), an Australian biopharmaceutical company focused on the developmen...

PubMed Articles [0 Results]

None

Clinical Trials [2 Associated Clinical Trials listed on BioPortfolio]

Prevascar in African Continental Group Scarring

There is considerable variation in scarring, within and between people, and between different ethnic groups. Individuals with more pigmented skin are more prone to severe scarring than th...

Juvista in the Non-surgical Improvement of Existing Scars

Renovo, a Biopharmaceutical company involved in the development of drugs to improve the appearance of scars and enhance wound healing, are proposing to carry out research in improving the ...

Companies [84 Associated Companies listed on BioPortfolio]

Renovo Neural Inc.

Renovo Neural Inc. (http://www.renovoneural.com/) is a privately held company in Cleveland, OH. The company is a specialized research organization providing services to biotech, ...

Renovo Limited

Renovo's core business activity is the development of innovative and efficacious approaches to prevent scarring and enhance tissue repair, from discovery phase to clinically proven commercial product....

Renovo plc

Renovo is the world leader in scar prevention and reduction research, developing pharmaceutical products to prevent and reduce scarring in the skin, blood vessels, eyes, nerves, internal organs, tendo...

Microsulis Medical Limited

Founded in 1997, Microsulis Medical Limited is a UK-based medical device company that exploits specialist intellectual property in medical microwave design to create therapeutic d...

Immunocore Limited

Immunocore Limited is developing innovative biological therapeutics to treat a range of cancers, chronic viral infections and diabetes. Immunocore is a privately owned biotechnology company located ...

More Information about "Renovo Limited" on BioPortfolio

We have published hundreds of Renovo Limited news stories on BioPortfolio along with dozens of Renovo Limited Clinical Trials and PubMed Articles about Renovo Limited for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Renovo Limited Companies in our database. You can also find out about relevant Renovo Limited Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Wound management
Anything that breaks the skin is a wound because when the skin is broken, there's a risk of germs getting into the body and causing an infection. Follow and track Wound Care News on BioPortfolio: Wound Car...


Corporate Database Quicklinks



Searches Linking to this Company Record